Abstract
The ability of the innate immune system to quickly recognize and respond to an invading pathogen is essential for controlling the infection. For this purpose, cells of the immune system express receptors which recognize evolutionarily conserved structures expressed by various pathogens but absent from host cells. In this review we focus on the nonclassical C-type lectin receptors including Dectin-1 whose role has been extensively characterized in the recognition and response to fungal pathogens. Dectin-1 is a type II transmembrane protein which binds β-1,3 and β-1,6 glucans. It is expressed on most cells of the innate immune system and has been implicated in phagocytosis as well as killing of fungi by macrophages, neutrophils and dendritic cells. The Dectin-1 cytoplasmic tail contains an immunoreceptor tyrosine based activation motif (ITAM) that signals in part through the spleen tyrosine kinase and in collaboration with Toll-like receptors. Although the main research focus has been on Dectin-1s role as a fungal and yeast pathogen recognition receptor, more recent studies suggest that Dectin-1 may have a broader function in pathogen recognition including a role in directing a macrophage response to mycobacterial infections.
Keywords: Pattern recognition receptors, Dectin-1, signaling, mycobacteria, fungi, glucans, C-type lectin
Current Drug Targets
Title: The Pattern Recognition Receptor Dectin-1: From Fungi to Mycobacteria
Volume: 9 Issue: 2
Author(s): J. S. Schorey and C. Lawrence
Affiliation:
Keywords: Pattern recognition receptors, Dectin-1, signaling, mycobacteria, fungi, glucans, C-type lectin
Abstract: The ability of the innate immune system to quickly recognize and respond to an invading pathogen is essential for controlling the infection. For this purpose, cells of the immune system express receptors which recognize evolutionarily conserved structures expressed by various pathogens but absent from host cells. In this review we focus on the nonclassical C-type lectin receptors including Dectin-1 whose role has been extensively characterized in the recognition and response to fungal pathogens. Dectin-1 is a type II transmembrane protein which binds β-1,3 and β-1,6 glucans. It is expressed on most cells of the innate immune system and has been implicated in phagocytosis as well as killing of fungi by macrophages, neutrophils and dendritic cells. The Dectin-1 cytoplasmic tail contains an immunoreceptor tyrosine based activation motif (ITAM) that signals in part through the spleen tyrosine kinase and in collaboration with Toll-like receptors. Although the main research focus has been on Dectin-1s role as a fungal and yeast pathogen recognition receptor, more recent studies suggest that Dectin-1 may have a broader function in pathogen recognition including a role in directing a macrophage response to mycobacterial infections.
Export Options
About this article
Cite this article as:
Schorey S. J. and Lawrence C., The Pattern Recognition Receptor Dectin-1: From Fungi to Mycobacteria, Current Drug Targets 2008; 9(2) . https://dx.doi.org/10.2174/138945008783502430
DOI https://dx.doi.org/10.2174/138945008783502430 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Current Pharmaceutical Design Thiazolides, a Novel Class of Anti-Infective Drugs, Effective Against Viruses, Bacteria, Intracellular and Extracellular Protozoan Parasites and Proliferating Mammalian Cells
Anti-Infective Agents Rapid Analysis of Pharmacology for Infectious Diseases
Current Topics in Medicinal Chemistry Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Immune Monitoring to Predict the Development of Infections After Immunosuppression for Solid Organ Transplantation and Autoimmune Diseases
Current Drug Safety Vitamin D: A Micronutrient Regulating Genes
Current Pharmaceutical Design Editorial [Hot Topic: HIV Drug Design (Executive Editor: A.S. Bourinbaiar)]
Current Pharmaceutical Design Nanodelivery Systems for Mucosal Vaccines
Recent Patents on Nanomedicine Anti-Oxidative Effect of Curcumin Against Tert-Butylhydroperoxide Induced Oxidative Stress in Human Erythrocytes
The Natural Products Journal Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) P-Glycoprotein - Implications of Metabolism of Neoplastic Cells and Cancer Therapy
Current Cancer Drug Targets Efficient Antibacterial Agents: A Review of the Synthesis, Biological Evaluation and Mechanism of Pleuromutilin Derivatives
Current Topics in Medicinal Chemistry Glycosylation Employing Unprotected Carbohydrate Acceptor Components
Current Organic Chemistry A Computational Study of Molecular Interactions and In Vitro Antibacterial Activity of 6-Substituted Quinoline Carboxylic Acid Derivatives as DNA Gyrase Inhibitors
Letters in Drug Design & Discovery Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Deciphering the Antimicrobial Activity of Phenanthroline Chelators
Current Medicinal Chemistry Xanthone: A Promising Antimycobacterial Scaffold
Medicinal Chemistry Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows
Endocrine, Metabolic & Immune Disorders - Drug Targets Dihydrofolate Reductase as a Target for Chemotherapy in Parasites
Current Pharmaceutical Design Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities
Current Pharmaceutical Design